Education
About Us
Working with TipRanks
Follow Us
Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
AARD Stock Chart & Stats
$12.91
--
Market closed
$12.91
--
Day’s Range― - ―
52-Week Range$4.88 - $19.58
Previous CloseN/A
VolumeN/A
Average Volume (3M)166.37K
Market Cap
$273.47M
Enterprise Value$234.73M
Total Cash (Recent Filing)$126.35M
Total Debt (Recent Filing)$545.00K
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Apr 06, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding21,773,272
10 Day Avg. Volume148,283
30 Day Avg. Volume166,372
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-3.38
Price to Sales (P/S)0.00
P/FCF Ratio-10.15
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-23.47K
Enterprise Value/Ebitda-4.51
Forecast
1Y Price Target
$33.00Price Target Upside155.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Enrollment And RetentionComplete continuation of HERO trial completers into the open-label extension, coupled with regulatory clearances in multiple countries and the addition of younger patients, signals strong patient engagement and supports smooth advancement of pivotal development.
Combination Therapy And Market PositioningPreclinical and clinical data indicate ARD-201 can enhance weight loss when paired with low-dose GLP-1 agents and may enable dose reduction to improve tolerability, offering a distinct pathway to commercial uptake as an oral adjunct or off-ramp to GLP-1 therapy.
Safety And Tolerability ProfileARD-101 has shown a clean safety and tolerability profile with low rates of treatment-emergent adverse events and no severe events reported in trials, which could differentiate it from current Prader-Willi syndrome care.
Bears Say
Commercial Adoption And Competitive DynamicsStrong patient and prescriber preference for entrenched GLP-1-based medicines could limit uptake of ARD-201 unless it provides clear advantages in effectiveness, tolerability, or convenience.
Efficacy Risk Versus Established TherapiesA high bar exists for standalone weight-loss agents, and failure of ARD-201 to match the efficacy and tolerability of established GLP-1 therapies would pose significant execution risk for broader market acceptance.
Regulatory And Payer Acceptance RiskIf ARD-201 cannot demonstrate clear clinical benefit relative to GLP-1 options, obtaining regulatory approvals and favorable reimbursement for primary obesity use could be challenging.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $4.88 and its highest was $19.58 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $273.47M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
Aardvark Therapeutics, Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 59 days.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Aardvark Therapeutics, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.799 by $0.049.
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Undervalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate is -0.84.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,773,272 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Aardvark Therapeutics, Inc. reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.799. Following the earnings report the stock price went down -8.656%.
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aardvark Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (155.62% Upside)
$33.00 (155.62% Upside)
Insider Transactions
Bought Shares
Worth $144.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.2%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
Fundamentals
Return on Equity
-48.06%
Trailing 12-Months
Asset Growth
59.10%
Trailing 12-Months
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
AARD Stock 12 Month Forecast
Average Price Target
$33.00
▲(155.62% Upside)
Technical Analysis
Ownership Overview
42.42% Insiders
3.06% Mutual Funds
26.38% Other Institutional Investors
22.79% Public Companies and Individual Investors